Cabaletta Bio, Inc. insider trading
Every open-market purchase and sale by Cabaletta Bio, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Insider purchases, 5 years $296,209 8 trades by 8 insiders
3 months later: median +35.5% (+31.4% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Cabaletta Bio, Inc.’s insiders pay?
From December 14, 2020 to January 21, 2026, 12 insiders reported 12 open-market purchases and 4 sales not made under a pre-set plan in Cabaletta Bio, Inc. After sales, the shares moved −88.5% against the index over 12 months (a negative figure means selling was the right call).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Nichtberger Steven | President & CEO | 3 | — | — | 0 | — | January 21, 2026 |
| Binder Gwendolyn | President, Science & Tech. | 2 | — | — | 0 | — | January 21, 2026 |
| Simon Mark | Director | 2 | — | — | 0 | — | January 21, 2026 |
| 5am Partners V, LLC | 10% owner | 0 | — | — | 1 | −64.9% (1) | November 3, 2021 |
| 5am Ventures V, L.P. | 10% owner | 0 | — | — | 1 | −86.1% (1) | September 9, 2021 |
| Chang David J. | Chief Medical Officer | 1 | — | — | 0 | — | January 21, 2026 |
| Gavel Steve | Chief Commercial Officer | 1 | — | — | 0 | — | January 21, 2026 |
| Gerard Michael | General Counsel | 1 | — | — | 0 | — | January 21, 2026 |
| Marda Anup | Chief Financial Officer | 1 | — | — | 0 | — | October 18, 2022 |
| Rocklage Scott M | 10% owner | 0 | — | — | 1 | −100.4% (1) | January 12, 2021 |
| Schwab Andrew J. | 10% owner | 0 | — | — | 1 | −102.5% (1) | December 14, 2020 |
| Tomasello Shawn | Director | 1 | — | — | 0 | — | January 21, 2026 |